Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.
RheumMadness is an online tournament in which a bracket of teams, representing key learning concepts in rheumatology, compete against each other in a series of head-to-head matchups, much like basketball teams in the NCAA’s March Madness. The 2023 tournament theme was The All Star Season. Each team represented one all star article competing to be…
Rheumatologists living in Ukraine press on with their work of treating patients despite the ongoing war that began with a Russian military invasion.
A tribute to the life and distinguished career of Naomi Rothfield, MD, MACR.
The ACR and the ARP are preparing to relaunch the Advanced Rheumatology Course (ARC) with a fresh look and an enhanced format to facilitate the learner experience. Since its debut, the ARC, formerly the Nurse Practitioner and Physician Assistant Postgraduate Rheumatology Training Program, has been a valuable resource for hundreds of nurse practitioners (NPs), physician…
Fractures in Patients with SSc By Zsuzsanna McMahan, MD, MHS Why was this study done? To minimize disability due to systemic sclerosis (SSc), it’s important to prevent and manage complications. Many SSc complications and related medications may increase the risk for osteoporosis and fracture. We sought to identify modifiable risk factors for fracture in patients…
Discussions between clinicians and their patients about complementary aspects of their care just got easier with the release of the 2022 ACR Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.
We were sad to learn that Rodanthi C. Kitridou, MD, MACR, passed away July 6, 2023, after a long illness. Dr. Kitridou was the longtime director of clinical rheumatology at at LAC/USC Medical Center in Los Angeles.
Research suggests the use of non-steroidal anti-inflammatory drugs may mask the amount of sacroiliac joint inflammation found on MRI in patients with axial spondyloarthritis.
TLL-018, a Janus kinase 1/tyrosine kinase 2 inhibitor, proved more effective for treating patients with RA than tofacitinib, according to a study by Zeng et al.